The primary endpoint of HiSCR75 at week 16 did not meet statistical significance in the Non-Responder Imputation (NRI) primary analysis.
HiSCR75 did meet statistical significance at week 16 in a Last Observation Carried Forward sensitivity analysis.
HiSCR response rates of izokibep 160mg weekly (QW) were consistent with Part A open label results, demonstrating early onset of HiSCR100 at week 4, increasing through week 12 to 38% of patients in the Independently Conducted Pre-Planned Interim Analysis.
Response was dose ordered, and safety was consistent with prior izokibep experience and not dose-limiting.
Izokibep appears to be demonstrating consistent early and high orders of response without safety or tolerability limitation.
Conference call and webcast to be held at 5:30 p.m. ET today.
ACELYRIN will host a conference call and webcast today, September 11, 2023, at 5:30 p.m. ET to review these trial results. A live webcast of the conference call can be accessed in the “Investors & Media” section of ACELYRIN’s website at www.acelyrin.com. A recording of the webcast will be available approximately two hours after the event, and will be archived on the Company’s website for approximately 30 days.
https://finance.yahoo.com/news/acelyrin-inc-announces-top-line-200500307.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.